Announcements Trials
Browse Landscape

Phase

Phase 2 76Phase 1 18Phase 1/2 17Phase NA 5Phase 3 3Phase EARLY_PHASE1 2Phase 2/3 2Phase 4 1

Status

Unknown 2Recruiting 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1

Conditions

Epstein-Barr Virus Infections 1EGFR Positive Non-small Cell Lung Cancer 1

Interventions

fludarabine 17Cyclophosphamide 16Positron Emission Tomography Computed Tomography 4Oncolytic Virotherapy 4Metformin 468Ga-pentixafor 4lenvatinib 3Radiosurgery 3Pemetrexed 3Paclitaxel 3Melphalan 3Immunotherapy, Adoptive 3Gemcitabine 3Cholestanetriol 26-Monooxygenase 3Carboplatin 3toripalimab 2sintilimab 2pembrolizumab 2gallium Ga 68 dotatate 2gallium 68 PSMA-11 2fludarabine phosphate 2alpha-Synuclein 2Progesterone 2Nivolumab 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Interleukin-2 2Influenza Vaccines 2Fluorodeoxyglucose F18 2Ethiodized Oil 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Unknown × toripalimab × Clear all
NCT06208033 2024-01-17

SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)

Fujian Cancer Hospital

Phase EARLY_PHASE1 Unknown
40 enrolled
Thoracic

EGFR Positive Non-small Cell Lung Cancer

NCT04690036 2021-06-29

PD-1 Antibody for Reactive EBV After BMT

Beijing Friendship Hospital

Phase EARLY_PHASE1 Unknown
20 enrolled

Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡